19 mai 2022 – The Confederation has signed a contract with Pfizer AG for the procurement of 12,000 packs of Paxlovid. Paxlovid consists of two preparations with active ingredients nirmatrelvir and ritonavir, which are taken as tablets. The first treatments will be available as early as May 2022 for certain high-risk patients in certain cantonal centres authorised to dispense it. In a second phase, the prescription drug will also be available through general practitioners and pharmacies. The costs for outpatient use will be covered by the federal government. This medicinal product is not currently authorised but can already be used to treat Covid-19 patients during the current authorisation procedure, based on Covid-19 Ordinance 3.

For more information, see here.